In immunocompetent mice bearing mEER tumors, xevinapant (100 mg/kg by oral gavage, 5 days/week for 3 weeks) added to cisplatin and radiotherapy delayed tumor growth and prolonged time to the humane survival endpoint compared with chemoradiotherapy plus vehicle. This was a combination result in a specific tumor model. [3]
In a separate mEER tumor-growth comparison, anti-CD8 treatment reduced chemoradiotherapy-associated tumor control (P = 0.0317), while its effect in the xevinapant combination group was not statistically significant (P = 0.182). The result limits an assumption that improved local control necessarily reflects stronger CD8-mediated immunity; nonsignificance does not establish equivalence or complete CD8 independence. [3]
Xevinapant plus chemoradiotherapy in mEER tumors
Animal study · Female C57BL/6 wild-type mice, 8–14 weeks old, with subcutaneous mEER head-and-neck tumors; 11–12 mice/group in Figure 1B–C [3]
Adding xevinapant to CRT delayed tumor growth and prolonged time to the humane survival endpoint relative to CRT plus vehicle. Vehicle, xevinapant-alone and cisplatin-alone arms were also displayed; no monotherapy efficacy is inferred from the combination.
Conditions shared by the study groups
- Vehicle
- 0.6% malic acid (w/v) in 85 mmol/L sodium acetate buffer, pH 4.5
- CRT plus xevinapant
- Model: Female C57BL/6 wild-type mice, 8–14 weeks old, with subcutaneous mEER head-and-neck tumors; 11–12 mice/group in Figure 1B–C
- Route: Xevinapant: oral gavage; cisplatin: intraperitoneal; RT: localized irradiation
- Frequency: Xevinapant: 5 consecutive days/week; RT: alternate days; cisplatin: single dose depicted on day 14 in Figure 1A
- Treatment course: Xevinapant: 3 weeks
- CRT plus vehicle comparator
- Model: Female C57BL/6 wild-type mice, 8–14 weeks old, with subcutaneous mEER head-and-neck tumors; 11–12 mice/group in Figure 1B–C
- Route: Cisplatin: intraperitoneal; RT: localized irradiation
- Frequency: RT on alternate days; cisplatin single dose depicted in Figure 1A
- Treatment course: Comparator followed alongside combination
Methods and source locations
Compound reported in the paper: Xevinapant
Published xevinapant combination experiment in an immunocompetent mouse model; not a product-lot, monotherapy or clinical-efficacy claim.
Figure 1A–C; Results first subsection; Methods, mouse models, in vivo tumor treatments and statistics
Tumor growth: CRT plus xevinapant versus CRT plus vehicle: Tumor-growth AUC comparison; plotted data mean ± SEM. Caption: 11–12 mice/group; representative of ≥2 independent experiments, not a pooled animal count. — Figure 1B (displayed comparison); statistical methods
Time to humane survival endpoint: CRT plus xevinapant versus CRT plus vehicle: Kaplan–Meier/log-rank Mantel–Cox. Euthanasia at any tumor dimension 15 mm or weight loss ≥20% of baseline; this is not unqualified natural survival. — Figure 1C; mouse-model and statistical methods
CRT plus xevinapant · Figure 1A–C; in vivo treatment methods
CRT plus vehicle comparator · Figure 1A–C; in vivo treatment methods
Anti-CD8 treatment modifies CRT response differently with xevinapant
Animal study · mEER tumors in C57BL/6 mice; 11–15 mice/treatment group [3]
An anti-CD8 treatment comparison reduced tumor control in the CRT group but did not significantly change tumor growth in the CRT-plus-xevinapant group. This records the treatment comparison; it does not prove complete CD8 depletion or identify the cause of immune impairment.
Conditions shared by the study groups
- Route
- Xevinapant: oral gavage; anti-CD8/isotype: intraperitoneal
- Frequency
- Xevinapant: 5 consecutive days/week; antibody maintenance twice weekly
- Treatment course
- Xevinapant 3 weeks; antibody loading 24 h before treatment initiation, total 10 antibody doses per Figure 1 caption
- Vehicle
- 0.6% malic acid (w/v) in 85 mmol/L sodium acetate buffer, pH 4.5
- CRT plus xevinapant, with anti-CD8 versus isotype
- Model: mEER tumors in C57BL/6 mice; 11–15 mice/treatment group
- Reported limits: Direct depletion efficiency not verified from acquired main figure.
Methods and source locations
Compound reported in the paper: Xevinapant
Observed anti-CD8/isotype tumor-growth comparisons in this model; mechanistic independence remains limited.
Figure 1D; caption and first Results subsection; in vivo treatment and statistics methods
CRT: anti-CD8 versus isotype tumor growth: Tumor-growth AUC comparison; anti-CD8 associated with loss of tumor control. Mean ± SEM; 11–15 mice/group, representative of ≥2 independent experiments. — Figure 1D left panel; caption and Results first subsection
CRT plus xevinapant: anti-CD8 versus isotype tumor growth: No statistically significant change in tumor growth under the reported comparison; not evidence of equivalence or a validated zero effect. — Figure 1D right panel; caption and Results first subsection
CRT plus xevinapant, with anti-CD8 versus isotype · Figure 1A,D and caption; in vivo treatment methods